Trial Activity Trends
Comparing 2024-2025 vs 2020-2021 trial starts by indication
Rising Indications
+30% or more trial activity growth
Liver Failure Hepatology
'20
'21
'22
'23
'24
'25
'26
+240%
5→17
Obesity Metabolic
'20
'21
'22
'23
'24
'25
'26
+225%
152→494
Stroke Cardiovascular
'20
'21
'22
'23
'24
'25
'26
+211%
91→283
Constipation Gastrointestinal
'20
'21
'22
'23
'24
'25
'26
+191%
11→32
Immune Thrombocytopenia Rare Disease
'20
'21
'22
'23
'24
'25
'26
+154%
37→94
Arrhythmia Cardiovascular
'20
'21
'22
'23
'24
'25
'26
+143%
7→17
Bipolar Disorder CNS
'20
'21
'22
'23
'24
'25
'26
+136%
14→33
Vitiligo Dermatology
'20
'21
'22
'23
'24
'25
'26
+133%
12→28
Hypertrophic Cardiomyopathy Cardiovascular
'20
'21
'22
'23
'24
'25
'26
+129%
7→16
Alopecia Dermatology
'20
'21
'22
'23
'24
'25
'26
+113%
32→68
Lupus Immunology
'20
'21
'22
'23
'24
'25
'26
+105%
140→287
ADHD CNS
'20
'21
'22
'23
'24
'25
'26
+94%
17→33
Anxiety CNS
'20
'21
'22
'23
'24
'25
'26
+91%
43→82
Benign Prostatic Hyperplasia Urology
'20
'21
'22
'23
'24
'25
'26
+90%
10→19
GERD Gastrointestinal
'20
'21
'22
'23
'24
'25
'26
+89%
9→17
Stable Indications
-30% to +30% change
Ankylosing Spondylitis Immunology
'20
'21
'22
'23
'24
'25
'26
+25%
1720→2146
Solid Tumor (Advanced) Oncology
'20
'21
'22
'23
'24
'25
'26
+27%
1601→2027
Non-Hodgkin Lymphoma Oncology
'20
'21
'22
'23
'24
'25
'26
+16%
936→1085
Breast Cancer Oncology
'20
'21
'22
'23
'24
'25
'26
-4%
914→881
ALL Oncology
'20
'21
'22
'23
'24
'25
'26
-2%
514→506
Prostate Cancer Oncology
'20
'21
'22
'23
'24
'25
'26
+7%
453→483
Sarcoma Oncology
'20
'21
'22
'23
'24
'25
'26
-23%
397→304
Lung Cancer (General) Oncology
'20
'21
'22
'23
'24
'25
'26
-27%
396→291
AML Oncology
'20
'21
'22
'23
'24
'25
'26
+29%
284→367
Multiple Myeloma Oncology
'20
'21
'22
'23
'24
'25
'26
+7%
249→267
Declining Indications
-30% or more trial activity decline
COVID-19 Infectious Disease
'20
'21
'22
'23
'24
'25
'26
-91%
1957→185
Hepatitis C Infectious Disease
'20
'21
'22
'23
'24
'25
'26
-72%
25→7
Fabry Disease Rare Disease
'20
'21
'22
'23
'24
'25
'26
-50%
6→3
Muscle Spasm Musculoskeletal
'20
'21
'22
'23
'24
'25
'26
-43%
7→4
Merkel Cell Carcinoma Oncology
'20
'21
'22
'23
'24
'25
'26
-39%
31→19
Melanoma Oncology
'20
'21
'22
'23
'24
'25
'26
-37%
403→255
NASH/NAFLD Metabolic
'20
'21
'22
'23
'24
'25
'26
-34%
115→76
Myelofibrosis Oncology
'20
'21
'22
'23
'24
'25
'26
-31%
86→59
Pneumonia Respiratory
'20
'21
'22
'23
'24
'25
'26
-31%
179→124
Showing top 10 rising and declining trends
Upgrade to Pro for full trend analysis and export capabilities
See Pro FeaturesMethodology: Compares average trial starts in 2024-2025 vs 2020-2021.
Sparklines: Show trial volume 2020→2026 (left to right).